GSK: Investors will be looking for early signs that drugs giant will hit newly issued sales and earnings targets
For 2022, the City has been told to expect sales growth of 5% to 7%, leading to a 12% to 14% increase in operating profits
Company
GSK PLC
LON:GSK
GSK PLC will be a fully focused biopharma company following the demerger of its world-leading consumer healthcare business, Haleon, in July 2022. The company will prioritise innovation in vaccines and specialty medicines, maximising the increasing opportunities to prevent and treat disease.
746 stories · page 13 of 38
GSK increases dividend expectations as part of share consolidation
Analysts were also adjusting their forecasts, with Barclays saying many clients are "optimistic with regards to the near-term momentum" but others are in 'wait and see' mode
Five at Five: FTSE 100 rallies, Tech pivot?, Welcome Haleon, Celsius black hole
Here’s Proactive’s round-up of the top financial stories of the day, with helpful links taking you directly to the news
What 'New GSK' will look like after the Haleon spin-off
‘New GSK’ will be focused on four areas: infectious diseases, HIV, oncology and immunology, with analysts seeing stronger growth than continental peer group
GSK begins Haleon spin-off process ahead of Monday's listing
For each GSK share owned investors will get a new share in Haleon, which will start trading on Monday
GSK applies for shingles drug label expansion in Japan
It wants doctors to be able to prescribe Shingrix to at-risk groups over the age of 18, including those with compromised immune systems
Investor views on GSK 'significantly swing towards positive' ahead of Haleon spin-off
Those who still have negative views are cautious about long-term forecasts given "a pipeline that is still somewhat work-in-progress"
GlaxoSmithKline needs to be better in pharma arena, suggests Barclays
Barclays upped its forecasts for GSK’s Respiratory Syncytial Virus vaccine following a 'positive' readout
What investors need to know as GSK and Pfizer spin off Haleon
Some analysts see the valuation well short of the £50bn tabled by Unilever, while others reckon GSK will have divested itself of a major "headache"
GSK seeks approval for respiratory vaccine after trials show 'meaningful efficacy'
GSK said the vaccine showed “statistically significant and clinically meaningful efficacy” and no “unexpected safety concerns” were observed
GSK’s Priorix MMR vaccine gets US FDA approval
"We're proud to make Priorix available in the US for the first time, adding a choice for providers to help protect patients against these highly-contagious diseases," said Judy Stewart, senior vice president and head of US Vaccines, GSK
GSK says Haleon spin-out expected to list on LSE in July
Consumer health company Haleon’s ordinary shares are expected to be admitted to the London Stock Exchange on 18 July
GlaxoSmithKline bolsters its vaccines R&D pipeline with US$3.3bn swoop for American drug developer
It is acquiring Affinivax Inc, which gives it access to a technology being developed to treat pneumococcal diseases such as pneumonia
GlaxoSmithKline's cervical cancer drug wins Chinese approval
The authorities there have said that Cervarix will be administered in two doses
GSK hikes factory workers pay after union calls out derisory offer
Workers had been offered a 2.75% pay rise, a fall in real terms, even after the company made £8.8bn operating profits last year
GlaxoSmithKline: What's the difference between a 'buy idea' and neutral recommendation?
Yeah, we don't know either. Answers on a postcard please...
GlaxoSmithKline's RSV jab progress prompts broker upgrade
The broker has raised its share price target to 1,850p from 1,700p
Hay fever tablets on low supply, say Boots and Superdrug
Its a tough time for hay fever sufferers and sunflower oil lovers
GlaxoSmithKline shares look at five-year highs as activists go quiet
“The end of the pandemic’s been a good thing for GSK"
GlaxoSmithKline sales bounce higher after Covid treatment boost
The total dividend this year will be cut by 35% following the demerger of its consumer healthcare arm Haleon